Carvacrol Reduces Irinotecan-Induced Intestinal Mucositis Through Inhibition of Inflammation and Oxidative Damage via TRPA1 Receptor Activation.

50
The Effect of Carvacrol on Enteric Viruses.
December 13, 2016
1296x728_oregano_oil-benefits_uses_and_more
Bio-Efficacy of the Essential Oil of Oregano (Origanum vulgare Lamiaceae. Ssp. Hirtum).
January 5, 2017

Carvacrol Reduces Irinotecan-Induced Intestinal Mucositis Through Inhibition of Inflammation and Oxidative Damage via TRPA1 Receptor Activation.

Oral cancer medical concept as a mouth with malignant disease cells with 3D illustration elements.

Oral cancer medical concept as a mouth with malignant disease cells with 3D illustration elements.

Alvarenga EM1Souza LK1Araújo TS1Nogueira KM1Sousa FB1Araújo AR2Martins CS3Pacífico DM3de C Brito GA3Souza EP3Sousa DP4Medeiros JV5.

Author information

  • 1Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Federal University of Piauí, Parnaíba, PI, Brazil.
  • 2Biotechnology and Biodiversity Center Research, BIOTEC, Federal University of Piauí, Parnaíba, PI, Brazil.
  • 3Postgraduate Program in Morphofunctional Sciences, Department of Morphology, Faculty of Medicine, Federal University Ceará, Fortaleza, CE, Brazil.
  • 4Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.
  • 5Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Federal University of Piauí, Parnaíba, PI, Brazil. Electronic address: jandvenes@ufpi.edu.br.

Abstract

Intestinal mucositis is an inflammatory process occurring in the intestinal mucosa and is a common side effect of irinotecan hydrochloride (CPT-11) based anticancer regimens. The transient receptor potential cation channel, subfamily A, member 1 (TRPA1) receptor is highly expressed in the intestinal mucosa and has the ability to identify cell damage signaling indicates its possible association with intestinal mucositis. Carvacrol is an agonist of the TRPA1 receptor and has anti-inflammatory properties. Thus, the aim of the present study was to verify the supposed anti-inflammatory and protective action of carvacrol via TRPA1 activation against intestinal mucositis induced by CPT-11 in mice. Briefly, mice were treated with either DMSO 2% or CPT-11 (75 mg/kg, per 4 days, i.p.) or the carvacrol (25, 75 or 150 mg/kg, per 8 days, i.p.) before CPT-11. In other group, the animals were pretreated with HC-030031, a TRPA1 antagonist, 30 min before treatment with carvacrol. On day 7, animal survival and bacteremia were assessed, and following euthanasia, samples of the jejunum were obtained for morphometric analysis and measurement of antioxidant and pro-inflammatory markers. Carvacrol was found to exert an anti-inflammatory action against CPT-11-induced intestinal mucositis through strong interactions with TRPA1 receptors; reduction in the production or release or both of pro-inflammatory cytokines (TNF-α, IL-1β, and KC); and decrease in other indicators of inflammation (MPO, NF-κB, COX-2) and oxidative stress (GSH, MDA, and NOx levels). It also contributed to the restoration of the tissue architecture of the villi and crypts in the small intestine, and improved clinical parameters such as survival, body mass variation, leukogram, and blood bacterial count. Thus, TRPA1 could be a target for future therapeutic approaches in the treatment of intestinal mucositis. You Can Read The Whole Article Here.

Leave a Reply

Your email address will not be published. Required fields are marked *